Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04686305
Title Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03)
Acronym DL03
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors AstraZeneca
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | FRA | ESP | CAN | BEL | AUS

Additional content available in CKB BOOST